| Literature DB >> 30631635 |
Derya Guzel1, Ahmet Bulent Yazici2, Esra Yazici2, Atila Erol2.
Abstract
The long-term use of opioids leads alternations in both innate-adaptive immune systems and other diagnostic hematologic cells. The purpose of this study is to evaluate the alterations of these parameters in patients with heroin/opioid addictions. Adults, meeting the Fifth Edition of the Diagnostic and Statistical Manual of Mental Disorders (DSM-5) criteria of the American Psychiatric Association regarding opioid use disorder (Heroin Group or HG, n = 51) and healthy controls (Control Group or CG, n = 50), were included in the study. All hematological parameters, inflammation indexes (neutrophil-lymphocyte ratio and platelet-lymphocyte ratio), and iron panel were compared with the controls. Mean corpuscular volume, red blood cell distribution width, mean corpuscular hemoglobin content, unsaturated iron-binding capacity, and total iron-binding capacity were significantly higher in HG compared to CG, while red blood cell count, hemoglobin, hematocrit, and serum iron levels were significantly lower. Additionally, platelet and platelet distribution width were significantly high while mean platelet volume was low in HG. Regarding the parameters related to immunity, white blood cell, neutrophil count, and neutrophil percentage were significantly high while lymphocyte percentage and basophils count were significantly low. Besides, inflammatory indexes were significantly higher in HG compared to CG. Intravenous administration of heroin resulted in lower levels of hemoglobin, hematocrit, and mean corpuscular volume than inhalation and intranasal administration. Our data demonstrated that chronic use of opioids is related to all of the hematologic series. The chronic use of opioid alters the immunologic balance in favor of innate immunity cells and changes the hematometric/morphometric characteristics of erythrocytes. What is more, the route of heroin administration should be taken into consideration as well. This study may lead to a better understanding of the hematological effects of heroin/opioid use in patients with relevant addictions.Entities:
Year: 2018 PMID: 30631635 PMCID: PMC6304569 DOI: 10.1155/2018/2036145
Source DB: PubMed Journal: J Addict ISSN: 2090-7850
Erythrocyte series and serum iron profile parameters of groups.
|
|
|
|
|
|
|
|---|---|---|---|---|---|
| Red Blood Cell Count (RBC, M/uL) | Mean ± Sd | 4.88±0.49 | 5.32±0.43 | 97.97 |
|
| Hemoglobin (HGB, g/dl) | Mean ± Sd | 14.60±1.28 | 15.45±1.26 | 98.98 |
|
| Hematocrit (HCT, %) | Mean ± Sd | 43.21±3.80 | 45.95±3.25 | 97.18 |
|
| Mean Corpuscular Hemoglobin (MCH, pg) | Mean ± Sd | 29.98±1.45 | 29.08±1.96 | 90.12 |
|
| Mean Corpuscular Hemoglobin Concentration (MCHC, g/dl) | Mean ± Sd | 33.81±1.16 | 33.57±0.94 | 95.56 | 0.257 |
| Red Cell Distribution Width (RDW, %) | Med ± IR | 15.60±1.20 | 14.90±1.97 | 95.65 |
|
| Mean Corpuscular Volume (MCV, fl) | Med ± IR | 88.80±4.90 | 86.90±3.95 | 97.36 |
|
| Serum Iron (SI, | Mean ± Sd | 66.00±28.11 | 102.44±35.80 | 92.89 |
|
| Unsaturated Iron Binding Capacity (UIBC, | Mean ± Sd | 246.08±58.42 | 188.17±58.45 | 98.95 |
|
| Total Iron Binding Capacity (TIBC, | Mean ± Sd | 311.92±49.16 | 292.11±43.74 | 98.08 |
|
∗Significant at the 0.05 level (two-tailed). #Significant at the 0.001 level (two-tailed). +Mean ± Standard Division (Mean ± SD) for parametric analysis and Median ± Interquartile (Med ± IR) range for nonparametric analysis. Welch-correction to the degrees of freedom (df).
Inflammatory series and platelet parameters of both groups.
|
|
|
|
|
|
|
|---|---|---|---|---|---|
| Platelet (PLT, K/uL) | Mean ± Sd | 263.73±72.22 | 233.90±54.30 | 92.80 |
|
| Mean Platelet Volume (MPV, fl) | Med ± IR | 6.77±1.08 | 8.72±2.10 | 79.44 |
|
| Plateletcrit (PCT, GSD) | Mean ± Sd | 0.19±0.05 | 0.20±0.04 | 93.18 | 0.154 |
| Platelet Distribution Width (PDW, %) | Med ± IR | 17.20±1.00 | 16.90±5.27 | 57.79 | 0.144 |
| White Blood Cell Count (WBC, K/uL) | Med ± IR | 8.55±3.59 | 7.50±1.68 | 75.48 |
|
| Neutrophils (NEUn, K/uL) | Med ± IR | 5.52±2.89 | 4.19±1.35 | 79.57 |
|
| Neutrophil (NEU%, K/uL) | Mean ± Sd | 63.50±7.60 | 56.47±7.56 | 98.97 |
|
| Lymphocytes (LYMn, K/uL) | Mean ± Sd | 2.51±0.96 | 2.60±0.65 | 88.09 | 0.558 |
| Lymphocyte (LYM%, K/uL) | Mean ± Sd | 27.22±7.16 | 34.88±7.09 | 98.98 |
|
| Monocytes (MONOn, K/uL) | Med ± IR | 0.50±0.33 | 0.50±0.18 | 81.14 | 0.311 |
| Monocytes (MONO %, K/uL) | Mean ± Sd | 6.18±1.76 | 6.35±1.74 | 98.98 | 0.624 |
| Eosinophils (EOSn, K/uL) | Med ± IR | 0.19±0.19 | 0.16±0.10 | 72.75 | 0.250 |
| Eosinophils (EOS%, K/uL) | Med ± IR | 2.11±1.81 | 1.88±1.33 | 86.38 | 0.696 |
| Basophils (BASOn, K/uL) | Mean ± Sd | 0.067±0.06 | 0.068±0.06 | 55.16 | 0.550 |
| Basophils (BASO%, K/uL) | Mean ± Sd | 0.77±0.34 | 0.84±0.47 | 89.12 | 0.421 |
| Platelet / lymphocyte ratio (PLR) | Med ± IR | 107.88±80.31 | 91.16±32.67 | 81.82 |
|
| Neutrophil / lymphocyte ratio (NLR) | Med ± IR | 2.31±1.42 | 1.61±0.95 | 78.36 |
|
∗Significant at the 0.05 level (two-tailed). #Significant at the 0.001 level (two-tailed). +Mean ± Standard Division (Mean ± SD) for parametric analysis and Median ± Interquartile (Med ± IR) range for nonparametric analysis. Welch-correction to the degrees of freedom (df).
Figure 1Mean and median count of hematological parameters.
Figure 2Comparison of the route of administration.